Bard Declares Quarterly Dividend

MURRAY HILL, N.J.--(BUSINESS WIRE)-- The Board of Directors of C. R. Bard, Inc. (NYSE: BCR) today declared a regular quarterly dividend of 24 cents per share on Bard's common stock. The current indicated annual dividend rate is 96 cents per share. The dividend is payable on November 6, 2015 to shareholders of record at the close of business on October 26, 2015.

C. R. Bard, Inc. (www.crbard.com), headquartered in Murray Hill, N.J., is a leading multinational developer, manufacturer and marketer of innovative, life-enhancing medical technologies in the fields of vascular, urology, oncology and surgical specialty products.

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current expectations, the accuracy of which is necessarily subject to risks and uncertainties. These statements are not historical in nature and use words such as “anticipate”, “estimate”, “expect”, “project”, “intend”, “forecast”, “plan”, “believe”, and other words of similar meaning in connection with any discussion of future operating or financial performance. Many factors may cause actual results to differ materially from anticipated results including product developments, sales efforts, income tax matters, the outcomes of contingencies such as legal proceedings, and other economic, business, competitive and regulatory factors. The company undertakes no obligation to update its forward-looking statements. Please refer to the Cautionary Statement Regarding Forward-Looking Information in our June 30, 2015 Form 10-Q for more detailed information about these and other factors that may cause actual results to differ materially from those expressed or implied.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151014006179/en/

C. R. Bard, Inc.
Investor Relations:
Todd W. Garner
Vice President, Investor Relations
908-277-8065

Media Relations:
Scott T. Lowry
Vice President and Treasurer
908-277-8365

Source: C. R. Bard, Inc.

You May Also Be Interested In

• PB2 Foods Introduces New PB2Go Cups, Bringing High-Protein Peanut Butter Snacking Anywhere
• Ascletis Announces U.S. FDA IND Clearance for Phase I Study of Once-Monthly Subcutaneously Administered GLP-1R/GIPR Dual Peptide Agonist, ASC35, for the Treatment of Obesity
• Advanced Rehabilitation, LLC Expands iKNOT Curriculum to Address Complex Regional Pain Syndrome & Chronic Upper Extremity Problems